Full Press Release Details
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced management's participation in the following investor conferences in August. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.
BTIG Biotechnology Conference
Virtual one-on-one meetings on August 8, 2022
13th Annual Wedbush PacGrow Healthcare Conference
Panel Series “Bullseye - Targeted Oncology - In with the New”
Tuesday, August 9, 2022, at 10:20 a.m. ET
Please find a link to the panel here
Management to participate virtually in one-on-one meetings on August 9 and 10, 2022
A webcast of the panel will be accessible under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will remain available for up to 90 days.
About Foghorn Therapeutics
Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
Michael Lampe, ScientPR (Media)
Hans Vitzthum, LifeSci Advisors (Investors)